FIPRecover News │ Feline Antiviral Industry Updates

Switch from GS-441524 Liquid to Tablets for FIP Cats

Learn how to safely switch from GS-441524 injections to tablets for FIP cats, ensuring stable dosing, treatment continuity, and relapse prevention guidance.

24th July 2026

GS-441524 Quality & FIP Treatment Failure in Europe

Low-quality GS-441524 may affect FIP treatment outcomes. Learn how purity, stability, and lab testing impact results and recovery in Europe.

23rd July 2026

GS-441524 Price vs Quality: How to Choose Safe FIP Care

Learn how GS-441524 purity, quality control, and manufacturing standards affect FIP treatment safety, effectiveness, and long-term recovery.

17th July 2026

GS-441524 for Cats: The Breakthrough FIP Treatment

Discover why GS-441524 is transforming FIP treatment in cats. Learn about recovery rates, antiviral therapy, and successful treatment outcomes.

16th July 2026

How Molnupiravir Fights FIP in Cats: Mechanism Explained

Explore how Molnupiravir works against FIP in cats, its antiviral mechanism, and how it helps veterinarians improve feline infectious peritonitis treatment.

10th July 2026

FIP GS-441524: Common Mistakes in First 14 Days

Discover common mistakes in the first 14 days of FIP GS-441524 treatment, including dosage errors and protocol gaps affecting early recovery in cats.

9th July 2026

FIPRecover Biotechnology Co., LTD.

FIPRecover Biotechnology Co., LTD. : Protecting Cats with Technology

Feline infectious peritonitis can be regarded as a “silent killer” threatening the lives of cats. This disease silently poses a threat to the lives of cats. To address the challenges brought by feline infectious peritonitis, FIPRecover Biotechnology Co., Ltd. has devoted all its energy to the research and development of pet disease treatment. It takes biotechnology as its core I want to bring new hope to those cats suffering from FIP.

As a professional company in the field of pet biopharmaceuticals, the company’s core business mainly focuses on the highly effective drug GS441524 and Molnupiravir. Clinically proven, this drug can precisely target the pathogenesis of FIP, inhibit viral replication, reduce inflammation, and help cats overcome adverse symptoms such as fever and ascites. From raw material procurement to every stage of production and processing, the company strictly controls every link, always adhering to international standards. With very meticulous quality control, it ensures the safety, efficacy and stability of the drugs, building a solid defense line against the side effects of the drugs.

The company’s mission is “to alleviate the suffering of kittens with fip and give them a new lease of life.” The company has gathered a team composed of experienced veterinarians and R&D experts to provide free disease consultation, medication guidance, and rehabilitation follow-up services for pet owners. The company collaborates with relevant organizations to carry out public health education, enabling FIP knowledge to be more widely popularized and improving the network for cat health protection. In the future, The company will continue to deepen its development in the field of pet biomedicine, using outstanding technology, products and services to safeguard the health of cats around the world, enabling more kittens to stay away from diseases and enjoy happy times to the fullest.

Getting all of the Nutrients you need simply cannot be done without supplements.

+8615898659128

shirley@fiprecover.com

Switch from GS-441524 Liquid to Tablets for FIP Cats

GS-441524 Quality & FIP Treatment Failure in Europe

GS-441524 Price vs Quality: How to Choose Safe FIP Care

GS-441524 for Cats: The Breakthrough FIP Treatment

How Molnupiravir Fights FIP in Cats: Mechanism Explained

FIP GS-441524: Common Mistakes in First 14 Days

Products

News

CONTACT US